RecruitingPhase 4NCT06841913

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

The Effects of Woodsmoke Exposure on Nasal Immune Responses to Influenza Infection in Normal Human Volunteers

Sponsor

University of North Carolina, Chapel Hill

Enrollment

112 participants

Start Date

Sep 26, 2025

Study Type

INTERVENTIONAL

Conditions

Influenza Smoke Exposure

Summary

This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symptoms, and reduces mucosal antibody production.

Eligibility

Min Age: 18 YearsMax Age: 49 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called LAIV nasal vaccine is chosen as a model viral infection, a biological treatment called Placebo for LAIV nasal vaccine is chosen as a model viral infection, and others for people with influenza and smoke exposure. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 49 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.